Cerebrasol has been performing first class contract research since 2001 and continues to support the biopharmaceutical industry in developing new treatments for diseases occurring throughout the central and peripheral nervous system. Our particular strength in electrophysiology allows investigation of function in the naïve and diseased state at all levels of the neuraxis, and the contribution our data and knowledge have made, and continue to make, to drug development programs worldwide is significant.
A small representation of the impact Cerebrasol has made to neuroscience research since 2001 can be demonstrated by some of our recent publications:
- Concentration-response relationship of the a7 nicotinic acetylcholine receptor agonist FRM-17874 across multiple in vitro and in vivo assaysO’Hare E, Jeggo R, Kim EM, Barbour B, Walczak JS, Palmer P, Lyons T, Page D, Hanna D, Meara JR, Spanswick D, Guo JP, McGeer EG, McGeer PL, Hobson P (2016) Lack of support for bexarotene as a treatment for Alzheimer’s disease. Neuropharmacology. 100:124-30.Puryear C, Whyment A, Walczak JS,Owens S, Sanchez-Morillo C (2017) Altered circuit function and plasticity in the hippocampus and prefrontal cortex of an animal model of treatment-resistant depression. European Neuropsychopharmacology. 27: S781Single Transcription Factor Conversion of Human Blood Fate to NPCs with CNS and PNS Developmental Capacity